Seysara is an anti-acne drug owned by Almirall. The active ingredient in Seysara is sarecycline hydrochloride. It was first authorized for market use on October 1, 2018 and it comes in tablet form for oral administration.
The generic version of Seysara might become available after February 9, 2033. This release date is estimated based on the drug patent expiries. The last patent for Seysara is expected to expire on February 9, 2033.
Seysara is effective as a treatment for acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients age 9 years and older. It operates by administering an effective amount of sarecycline hydrochloride. Specifically, it can be used to treat bacterial infections in inflammatory lesions, and also as a method for treating an inflammatory skin disorder in this demographic. This drug can be administered in 60 mg, 100 mg, or 150 mg equivalent doses.
Seysara has a total of 4 drug patents. None of these patents have expired yet. The earliest that challenges against these patents can be filed is on October 1, 2022. The last patent protects the crystalline salts of the active ingredient and expires on February 9, 2033. For more details on Seysara generic and patent, see below: